SAN DIEGO – In the wake of the U.S. Food and Drug Administration’s approval of Zepbound to treat moderate to severe obstructive sleep apnea, ResMed is ramping up its education to high-volume ...

Copyright 2025 The Associated Press. All Rights Reserved. A new poll from The Associated Press-NORC Center for Public Affairs Research looks at what U.S. adults think ...

The results, out after market close yesterday evening, came more than a month after the FDA approved Eli Lilly’s GLP-1 drug Zepbound (tirzepatide) as the first and only prescription drug to ...

In December and January, the US Food and Drug Administration (FDA) approved new therapies for lung cancer, atopic dermatitis, obstructive sleep apnea (OSA), and cystic fibrosis. The FDA also added a ...

Eli Lilly achieved the largest market capitalisation growth of 32.4% to $733bn in 2024, driven by strong demand for its weight-loss drugs, Mounjaro (tirzepatide) and Zepbound (tirzepatide). However, ...

Novartis was among the most prolific pharma dealmakers in 2024, a trend that it expects to continue with more bolt-on deals this year to set up for sustainable long-term growth. After signing 30 deals ...

With its offering of tirzepatide (branded as Mounjaro and Zepbound), Eli Lilly and Co. (NYSE: LLY) was another key pharma player in this new type of treatment for diabetes and obesity.

and Zepbound, for obesity. If you ask him what he's most excited about, it's not a daily, weekly, or even monthly medicine for weight loss or diabetes control. His eye is trained on a one-and-done ...

Eli Lilly and Co. reported that its FDA-approved weight-loss drug Zepbound (tirzepatide) outperformed Novo Nordisk A/S’s Wegovy (semaglutide) in the phase IIIb Surmount-5 trial.

Engagement on RMD's patient app (myAir) indicates ongoing momentum in therapy compliance, noting the potential of the rate of OSA diagnosis to step up from Zepbound's (GLP-1 drug from LLY ...

Today, GLP-1 drugs, including Wegovy, Mounjaro and Zepbound, have become household names and key tools in the fight against obesity: 1 in 8 American adults say they have used a GLP-1 drug ...

Related FDA approves weight-loss drug Zepbound to treat sleep apnea FDA says shortage of GLP-1 drug tirzepatide is over Merck reaches weight-loss drug deal worth up to $2 billion with China-based ...